Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03061474 · ClinicalTrials.gov registry record · Phase 2
Nicotinamide as an Early Alzheimer's Disease Treatment
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03061474 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 46 participants.
The verdict
NCT03061474, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer's disease (AD) dementia.
Interventions
- DRUG Placebo Comparator
- DRUG Nicotinamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03061474
The ClinicalTrials.gov registry entry for NCT03061474 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT03061474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03061474 about?
NCT03061474 is a clinical study titled "Nicotinamide as an Early Alzheimer's Disease Treatment". The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer's disease (AD) deme...
What is the current status of trial NCT03061474?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2017-07-12. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT03061474?
The interventions under investigation include: Placebo Comparator (DRUG), Nicotinamide (DRUG).
Who is sponsoring clinical trial NCT03061474?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.